2025-09-14 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the data provided, presented in a structured format.

**0) Overview**

*   **Ticker:** JNJ
*   **Company:** Johnson & Johnson
*   **Description:** Johnson & Johnson is a global healthcare company that develops and manufactures pharmaceuticals, medical devices, and consumer health products.

**1) Performance vs. S&P 500 (VOO)**

*   **JNJ Cumulative Return:** 19.06%
*   **VOO Cumulative Return:** 89.18%
*   **Absolute Difference:** -70.12%
*   **Relative Difference:** Max: 15.5, Min: -158.4, Current: -148.1, Relative Position: 5.9

**Analysis:** JNJ has significantly underperformed the S&P 500 over the analyzed period. The relative difference of 5.9 suggests that JNJ's performance is near the bottom of its historical range compared to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha   | Beta   | Cap(B) |
|------------|---------|--------|---------|--------|--------|
| 2015-2017  | -1.0%   | 0.0%   | -4.0%   | -0.9   | 336.5  |
| 2016-2018  | -9.0%   | 56.5%  | -4.0%   | -0.0   | 310.8  |
| 2017-2019  | 7.0%    | 56.5%  | -16.0%  | -0.1   | 351.3  |
| 2018-2020  | 22.0%   | 58.6%  | -5.0%   | -0.0   | 379.0  |
| 2019-2021  | 35.0%   | 59.4%  | -14.0%  | -0.0   | 412.0  |
| 2020-2022  | 12.0%   | 61.3%  | 5.0%    | 0.1    | 425.4  |
| 2021-2023  | -9.0%   | 61.3%  | -29.0%  | 0.5    | 377.5  |
| 2022-2024  | -28.0%  | 61.3%  | -55.0%  | 0.3    | 348.3  |
| 2023-2025  | 5.0%    | 70.1%  | -49.0%  | 0.1    | 428.8  |

**Analysis:**

*   **CAGR:** Fluctuates significantly over the periods, showing inconsistent growth.
*   **MDD:** High Maximum Drawdown values suggest substantial risk and volatility in returns.
*   **Alpha:** Predominantly negative alpha indicates underperformance compared to the benchmark, except for 2020-2022.
*   **Beta:** Low Beta values suggest that the stock is generally less sensitive to market movements.
*   **Cap(B):** Market capitalization shows varied growth over the periods.

**2) Recent Price Action**

*   **Current Price:** 178.06
*   **Previous Close:** 178.5
*   **Change:** -0.25
*   **5-day MA:** 177.488
*   **20-day MA:** 177.582
*   **60-day MA:** 167.3978

**Analysis:** The stock price is slightly down from the previous close. The 5-day and 20-day moving averages are very close, suggesting a period of consolidation. The 60-day moving average is significantly lower, indicating that the stock has been trending upward over the past two months.

**3) Indicators and Signals**

*   **MRI:** 0.3233 (Low Risk)
*   **RSI:** 45.70 (Neutral)
*   **PPO:** -0.3133 (Slightly Negative Momentum)
*   **Hybrid Signal:** Cash 67%, Sell 4.0% of holdings
*   **Recent Relative Divergence Change (20-day):** -2.8 (Short-term decline)
*   **Expected Return:** -1159.5% (Significant underperformance relative to S&P 500 over long term)

**Analysis:**

*   The Market Risk Indicator suggests a low-risk environment for the stock.
*   The RSI is neutral, indicating neither overbought nor oversold conditions.
*   The negative PPO suggests slightly negative momentum.
*   The hybrid signal recommends a high cash position and a slight selling of holdings, reflecting caution.
*   The recent decline in relative divergence indicates short-term underperformance.
*   The extremely negative expected return is a major red flag, suggesting significant underperformance relative to the S&P 500 over a long-term investment horizon.
* The price change {'price': 178.06, 'previousClose': 178.5, 'change': -0.25}가 작아서 특별한 이슈를 반영하지 않았음

**4) Recent News & Significant Events**

*   **[2025-09-13]** Jim Cramer Says Procter & Gamble Stock is “Still Way Too High”
*   **[2025-09-13]** How Strong Is Johnson & Johnson’s Value After FDA Nod for New Drug in 2025?
*   **[2025-09-12]** Prescription Drug Ads Face Big Changes. These Stocks Could Get Hurt the Most.
*   **[2025-09-12]** JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra
*   **[2025-09-12]** AbbVie Settles Rinvoq Patent Dispute: What It Means for the Stock
*   **[2025-09-12]** Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug?

**Analysis:**

*   The news is mixed. Some positive news includes the FDA nod for a new drug and seeking EU approval for another drug.
*   However, news about changes to prescription drug ads could negatively impact the stock.  News about competitors could also have an indirect impact.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (~2.25)
*   **Target Price:** 177.47 (Average)
    *   High: 200.00
    *   Low: 155.00
*   **Recent Rating Changes:** None (Indicates no recent shifts in analyst sentiment)

**Analysis:** Analysts generally have a "Buy" rating on the stock, with an average target price slightly below the current price.  This suggests analysts believe the stock is fairly valued around its current price. The lack of recent rating changes indicates stable sentiment.

**5) Recent Earnings Analysis**

| 날짜         | EPS  | 매출       |
|--------------|------|------------|
| 2025-07-24   | 2.3  | 23.74 B$   |
| 2025-04-23   | 4.57 | 21.89 B$   |
| 2024-10-23   | 1.12 | 22.47 B$   |
| 2024-07-25   | 1.95 | 22.45 B$   |
| 2025-07-24   | 1.95 | 22.45 B$   |

**Analysis:**

*   **Revenue:** Shows some fluctuation, with the most recent quarter showing a slightly higher revenue.
*   **EPS:**  The EPS varies significantly.  The 2025-04-23 quarter had a particularly high EPS. The latest EPS has recovered, but is still below the peak.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-06-30   | $23.74B    | 67.87%        |
| 2025-03-31   | $21.89B    | 66.40%        |
| 2024-12-31   | $22.52B    | 68.35%        |
| 2024-09-30   | $22.47B    | 69.01%        |
| 2024-06-30   | $22.45B    | 69.40%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE   |
|--------------|------------|-------|
| 2025-06-30   | $78.47B    | 7.06% |
| 2025-03-31   | $78.11B    | 14.08%|
| 2024-12-31   | $71.49B    | 4.80% |
| 2024-09-30   | $70.16B    | 3.84% |
| 2024-06-30   | $71.54B    | 6.55% |

**Analysis:**

*   **Revenue:**  Increasing revenue trend.
*   **Profit Margin:**  Profit margins are consistently high, indicating strong pricing power and efficient cost management.
*   **Equity:**  Equity has generally increased over the past year.
*   **ROE:**  ROE fluctuates. The high ROE in 2025-03-31 is an outlier.

**7) Overall Summary**

Johnson & Johnson (JNJ) presents a mixed picture. Here's a breakdown:

*   **Underperformance:**  The most significant concern is the substantial underperformance compared to the S&P 500, highlighted by the negative relative divergence and extremely negative projected return.
*   **Recent Price Action:**  The stock is in a period of consolidation, with price slightly down.
*   **Financial Strength:** JNJ maintains strong financials, characterized by high profit margins, increasing revenue, and growing equity.
*   **Mixed News:** Recent news presents a mixed outlook with both positive and negative potential impacts.
*   **Analyst Sentiment:** Analysts are generally positive, but the average target price is around current price.
*   **Low Risk/Neutral Indicators:** The Market Risk Indicator and RSI are at low risk and neutral levels.

**Conclusion:**

While JNJ boasts strong financials and is considered low-risk by some indicators, the significant underperformance relative to the S&P 500 and the negative projected return are major concerns.  Investors should carefully consider these factors before investing, and investigate the reasons behind the underperformance. Recent news events present both opportunities and risks, requiring careful monitoring.
